NICE to review guidance on Servier's Protelos after legal challenge
This article was originally published in Scrip
Executive Summary
The health technology appraisal body for England and Wales, NICE, will have to review its guidance on Servier's Protelos (strontium ranelate) for preventing osteoporotic fragility fractures, said a UK judge last week. Moreover, NICE must be clear in its reasoning when it reaches a different conclusion from that of "eminent bodies" such as the European Medicines Agency (EMA), according to the judgement.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.